| scholarly article | Q13442814 |
| P2093 | author name string | Ch Chen | |
| Ct Chou | |||
| Ky Su | |||
| Hp Wang | |||
| Ht Liao | |||
| Ws Chen | |||
| P2860 | cites work | Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies | Q24564876 |
| The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies | Q24628871 | ||
| Anti-keratin antibodies in rheumatoid arthritis | Q24678035 | ||
| Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement | Q24793557 | ||
| Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment | Q24800888 | ||
| Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis | Q24812184 | ||
| Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? | Q28202437 | ||
| The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis | Q28306666 | ||
| Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis | Q28345031 | ||
| Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis | Q33216887 | ||
| A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR. | Q33626291 | ||
| A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis | Q33982255 | ||
| How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value | Q34271223 | ||
| Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis | Q34344556 | ||
| Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis | Q34460622 | ||
| Genetics of rheumatoid arthritis: is there a scientific explanation for the human leukocyte antigen association? | Q34618174 | ||
| Epidemiology and genetics of rheumatoid arthritis | Q34731244 | ||
| Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. | Q34964320 | ||
| Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis | Q35111849 | ||
| Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases | Q35201241 | ||
| Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection | Q35547638 | ||
| Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage | Q35552357 | ||
| Filaggrin related antibodies among the aged | Q35552428 | ||
| Clinical utility of the anti-CCP assay in patients with rheumatic diseases | Q35553110 | ||
| Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement | Q35553375 | ||
| Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations | Q35553712 | ||
| Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis | Q73086332 | ||
| Ethnic variation in the clinical manifestations of rheumatoid arthritis: role of HLA-DRB1 alleles | Q73248982 | ||
| Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients | Q74613538 | ||
| The predictive power of anti-cyclic citrullinated peptide antibodies: window into understanding gene/ environment/immunity interactions | Q79840654 | ||
| Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations | Q80273423 | ||
| Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis | Q81248173 | ||
| Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population | Q81370033 | ||
| Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment | Q81430222 | ||
| Antibodies to cyclic citrullinated peptides in psoriatic arthritis | Q81463232 | ||
| Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis | Q82490820 | ||
| Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis | Q82704607 | ||
| Anti-cyclic citrullinated peptide antibodies in psoriasis patients without arthritis | Q83216557 | ||
| The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis | Q83841744 | ||
| Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. | Q35554481 | ||
| Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). | Q35554508 | ||
| Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). | Q35554533 | ||
| Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome | Q35554665 | ||
| Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression | Q35555003 | ||
| Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis | Q35555152 | ||
| Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis | Q35555882 | ||
| The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis | Q35636615 | ||
| Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome | Q35636845 | ||
| Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles | Q35636886 | ||
| The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis | Q36509983 | ||
| The contribution of HLA to rheumatoid arthritis. | Q38695243 | ||
| Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years | Q40213181 | ||
| Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis | Q40525673 | ||
| Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors | Q40532147 | ||
| Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. | Q41824468 | ||
| Palindromic rheumatism: a response to chloroquine | Q41887232 | ||
| Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases | Q41905224 | ||
| Long-term outcome of treating rheumatoid arthritis: results after 20 years | Q41913707 | ||
| The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis | Q42611991 | ||
| The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis | Q42657037 | ||
| Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis | Q42669706 | ||
| Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles | Q42674479 | ||
| A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination | Q42676934 | ||
| Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus | Q42988558 | ||
| Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents | Q43049284 | ||
| Smoking, rheumatoid factors, and rheumatoid arthritis | Q43053492 | ||
| Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies | Q43772895 | ||
| Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis | Q44176103 | ||
| Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis | Q44412980 | ||
| Smoking, gender and rheumatoid arthritis-epidemiological clues to etiology. Results from the behavioral risk factor surveillance system | Q44465611 | ||
| Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule | Q44504170 | ||
| Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis | Q44616885 | ||
| High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis | Q44661580 | ||
| Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins | Q44687984 | ||
| Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis | Q44725811 | ||
| Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica | Q44768557 | ||
| The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide | Q44791267 | ||
| Smoking history and serum cotinine and thiocyanate concentrations as determinants of rheumatoid factor in non-rheumatoid subjects | Q45029813 | ||
| The presence of citrullinated proteins is not specific for rheumatoid synovial tissue | Q45141270 | ||
| Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody | Q45184217 | ||
| Antibodies to viral citrullinated peptide in rheumatoid arthritis. | Q46971745 | ||
| A population study of rheumatoid factor in Iceland. A 5-year follow-up of 50 women with rheumatoid factor (RF) | Q50540227 | ||
| A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. | Q51373026 | ||
| Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. | Q53913243 | ||
| How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis | Q57789144 | ||
| Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis | Q58234987 | ||
| Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis | Q64461890 | ||
| The role of the laboratory in rheumatology. Rheumatoid factors | Q70268492 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 165-171 | |
| P577 | publication date | 2007-05-03 | |
| P1433 | published in | Biomarker Insights | Q4915072 |
| P1476 | title | The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases | |
| P478 | volume | 2 |
| Q92524356 | Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients |
| Q61796443 | C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro |
| Q89585479 | Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria |
| Q59356166 | Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database |
Search more.